OneStudyTeam
Digital tools for clinical trials
See open opportunities
Company mission
To pave the way to faster, predictable, and more accessible clinical trials.
Employees
201-500
HQ Location
Downtown Crossing, Boston, MA
OTTA INSIGHTS
Otta's take on OneStudyTeam
Sam Franklin
CEO of Otta
Clinical research remains a significant bottleneck on drug development. Much of this is due to the slow and unpredictable nature of patient enrolment. OneStudyTeam is tackling this problem with a platform that helps biopharma companies and research sites to enroll trials in three to four months instead of 18 months.
The company's tools are already being used by top-20 global biopharma companies such as Amgen, AstraZeneca, and Eli Lilly & Company, and across a total of over 5,000 research sites across 65 countries. In 2022, OneStudyTeam invested $220 million into improving diversity in clinical trials. This is a strong indicator of the company’s future-facing outlook and its impressive financial backing.
The business is scaling fast, reaching Unicorn status with its Series C round in 2021. If this trajectory continues, OneStudyTeam could become one of the leading names in the pharmaceutical and healthcare industries.
Total funding - $477.6m
Last 2 fundraises
Aug 2021
$220m
SERIES C
Apr 2022
$220m
SERIES D
This company has top investors
Company benefits
- Comprehensive health and wellness
- Generous parental leave
- Flexible paid time off
- 401(k) company match
Articles
Founders
Ralph Passarella
(CEO)Founded Reify Health in 2012 whilst completing a PhD/MD at The Johns Hopkins University School of Medicine. Also Co-Founder and Board Member at Signal Vine.
Michael Lin
(Executive Chairman)Studied at The Johns Hopkins University School of Medicine. Also Co-founder at Signal Vine.
For companies
Claim your profile to receive high quality applications from relevant candidates.
Claim profileOneStudyTeam is hiring for 5 jobs on Otta!
Software Engineering
Finance, Legal & Compliance
Sales & Account Management